JP2003501344A - （＋）−ベンラファキシン誘導体並びにその製造方法および使用方法 - Google Patents

（＋）−ベンラファキシン誘導体並びにその製造方法および使用方法

Info

Publication number
JP2003501344A
JP2003501344A JP2000585197A JP2000585197A JP2003501344A JP 2003501344 A JP2003501344 A JP 2003501344A JP 2000585197 A JP2000585197 A JP 2000585197A JP 2000585197 A JP2000585197 A JP 2000585197A JP 2003501344 A JP2003501344 A JP 2003501344A
Authority
JP
Japan
Prior art keywords
venlafaxine
human
pharmaceutically acceptable
desmethylvenlafaxine
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000585197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003501344A5 (enExample
Inventor
トーマス，ピー． ジェルッシ
セナナイェイク，クリサンタ，エイチ．
Original Assignee
セプラコア インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セプラコア インコーポレーテッド filed Critical セプラコア インコーポレーテッド
Publication of JP2003501344A publication Critical patent/JP2003501344A/ja
Publication of JP2003501344A5 publication Critical patent/JP2003501344A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2000585197A 1998-12-01 1999-12-01 （＋）−ベンラファキシン誘導体並びにその製造方法および使用方法 Pending JP2003501344A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11048698P 1998-12-01 1998-12-01
US60/110,486 1998-12-01
US09/450,691 1999-11-30
US09/450,691 US6197828B1 (en) 1998-12-01 1999-11-30 Derivatives of (+)-venlafaxine and methods of preparing and using the same
PCT/US1999/028306 WO2000032555A1 (en) 1998-12-01 1999-12-01 Derivatives of (+)-venlafaxine and methods of preparing and using the same

Publications (2)

Publication Number Publication Date
JP2003501344A true JP2003501344A (ja) 2003-01-14
JP2003501344A5 JP2003501344A5 (enExample) 2007-01-25

Family

ID=26808067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000585197A Pending JP2003501344A (ja) 1998-12-01 1999-12-01 （＋）−ベンラファキシン誘導体並びにその製造方法および使用方法

Country Status (5)

Country Link
US (1) US6197828B1 (enExample)
EP (1) EP1135358A1 (enExample)
JP (1) JP2003501344A (enExample)
CA (1) CA2352321A1 (enExample)
WO (1) WO2000032555A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008044936A (ja) * 2006-07-26 2008-02-28 Teva Pharmaceutical Industries Ltd Ｏ−デスメチルベンラファキシンの合成方法
JP2008545807A (ja) * 2006-07-26 2008-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｏ−デスメチルベンラファキシンの合成方法
JP2008546718A (ja) * 2006-04-17 2008-12-25 テバ ファーマシューティカル インダストリーズ リミティド 実質的に純粋なｏ−デスメチルベンラファキシン及びその調製方法。

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
CA2368083A1 (en) 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US20020035158A1 (en) * 1999-06-15 2002-03-21 American Home Products Corporation Enantiomers of N-desmethyl venlafaxine
AU5738700A (en) * 1999-06-15 2001-01-02 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
US20020022662A1 (en) * 1999-06-15 2002-02-21 American Home Products Corporation Enantiomers of O-desmethyl venlafaxine
AU5613600A (en) * 1999-06-15 2001-01-02 American Home Products Corporation Enantiomers of n-desmethyl venlafaxine
US6348494B1 (en) 2000-11-21 2002-02-19 American Home Products Corporation Ethers of o-desmethyl venlafaxine
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
SK12812002A3 (sk) * 2000-03-07 2003-08-05 Eli Lilly And Company Spôsob liečenia psoriázy
US20070059367A1 (en) * 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US20100196466A1 (en) * 2000-06-06 2010-08-05 Capricorn Pharma Inc. Drug delivery system
DE10042412B4 (de) * 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
TWI228118B (en) * 2000-08-30 2005-02-21 Ciba Sc Holding Ag Process for the preparation of substituted phenylacetonitriles
AU2002241764A1 (en) * 2000-10-19 2002-06-18 Teva Pharmaceutical Industries Ltd. Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
EA011451B1 (ru) 2001-02-12 2009-04-28 Уайт Новая соль сукцинат о-десметилвенлафаксина
UA80543C2 (en) * 2001-12-04 2007-10-10 Wyeth Corp Method for the preparation of o-desmethylvenlafaxine
WO2003082805A1 (en) 2002-03-28 2003-10-09 Synthon B.V. Low water-soluble venlafaxine salts
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
EP1485344A1 (en) 2002-03-28 2004-12-15 Synthon B.V. Venlafaxine besylate
US20030191347A1 (en) * 2002-03-28 2003-10-09 Rolf Keltjens Venlafaxine base
WO2003103603A2 (en) * 2002-06-10 2003-12-18 Wyeth Novel formate salt of o-desmethyl-venlafaxine
CN1232501C (zh) * 2002-11-29 2005-12-21 重庆凯林制药有限公司 用于制备万拉法新中间体的环己醇衍生物的制备工艺
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
WO2004056335A2 (es) * 2002-12-23 2004-07-08 Osmotica Costa Rica Sociedad Anonima Dispositivo de liberación que contiene venlafaxina y memantina
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
WO2005077340A1 (en) * 2004-02-06 2005-08-25 Wyeth Multiparticulate o-desmethylvenlafaxine salts and uses thereof
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US20060193912A1 (en) * 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co. Controlled release O-desmethylvenlafaxine formulations
EP1904046A4 (en) * 2005-07-06 2008-10-01 Sepracor Inc COMBINATIONS OF ESZOPICLON AND O-DESMETHYLVENLAFAXINE AND METHOD FOR THE TREATMENT OF MENOPAUSE AND HUMOR FLUCTUATIONS; ANXIETY AND COGNITIVE INTERFERENCE
US7595340B2 (en) 2005-07-15 2009-09-29 Wyeth Serotonin and norepinephrine reuptake inhibitor and uses thereof
US7687520B2 (en) 2005-07-15 2010-03-30 Wyeth Llc Serotonin and norepinephrine reuptake inhibitors and uses thereof
EP2998288B1 (en) * 2005-12-01 2022-08-24 ACADIA Pharmaceuticals Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
WO2007071404A1 (en) 2005-12-20 2007-06-28 Synthon B.V. Process for making desvenlafaxine
MX2007016179A (es) * 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
CN100506784C (zh) * 2006-05-22 2009-07-01 浙江苏泊尔制药有限公司 万拉法新的制备方法
US20090137846A1 (en) * 2006-07-26 2009-05-28 Valerie Niddam-Hildesheim Processes for the synthesis of O-Desmethylvenlafaxine
WO2008013995A2 (en) * 2006-07-26 2008-01-31 Teva Pharmaceutical Industries Ltd. Tridesmethylvenlafaxine and processes for the synthesis of o-desmethylvenlafaxine
US20080221356A1 (en) * 2006-07-26 2008-09-11 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
US20090069601A1 (en) * 2006-07-26 2009-03-12 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
ES2334765B1 (es) * 2006-08-04 2010-12-20 Medichem, S.A. Proceso mejorado para sintetizar la base libre de la desvenlafaxina ysales o solvatos de la misma.
EP2054374A1 (en) * 2006-08-08 2009-05-06 Merck Generics (UK) Limited Novel hydrate form of o-desmethyl venlafaxine succinate
WO2008112313A2 (en) * 2007-03-14 2008-09-18 Teva Pharmaceutical Industries Ltd. Processes for preparing solid states of o-desmethylvenlafaxine succinate
IN2007CH01519A (enExample) * 2007-07-16 2009-09-11 Matrix Lab Ltd
US20100330172A1 (en) * 2007-10-16 2010-12-30 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US20110118357A1 (en) 2007-10-26 2011-05-19 Generics Limited Process for preparing o-desmethylvenlafaxine
KR101343027B1 (ko) * 2007-11-26 2013-12-18 테바 파마슈티컬 인더스트리즈 리미티드 Ｏ-데스메틸벤라팍신 푸마레이트의 결정형
EP2074993A1 (en) 2007-12-19 2009-07-01 Biovail Laboratories International S.r.l. Venlafaxine-containing film-coated modified-release tablets
US8304578B2 (en) 2007-12-26 2012-11-06 Matrix Laboratories Limited Process for producing 1-[2-(dimethylamino)-1-(4-phenol)ethyl]cyclohexanol
EP2085377A1 (en) * 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Novel salts of O-desmethyl-venlafaxine
EP2252574A1 (en) * 2008-03-06 2010-11-24 Teva Pharmaceutical Industries Ltd. Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
KR100965527B1 (ko) 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
US20110112200A1 (en) * 2008-06-16 2011-05-12 Valerie Niddam-Hildesheim Solid states of o-desmethylvenlafaxine salts
WO2010062690A1 (en) * 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
EP2191822A1 (en) 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
US20110184067A1 (en) * 2010-01-25 2011-07-28 Intas Pharmaceuticals Ltd. O-desmethylvenlafaxine succinate polymorph & process for preparing thereof
CA2795023A1 (en) 2010-03-29 2011-10-06 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
EP2552419A2 (en) 2010-03-31 2013-02-06 Wockhardt Limited Modified release dosage form comprising desvenlafaxine or salts thereof
CZ303249B6 (cs) 2010-04-06 2012-06-20 Zentiva, K.S. Zpusob výroby 4-(2-(substituovaných)-1-(1-hydroxycyklohexyl)ethyl)fenolu O-demethylací jejich methyletheru pomocí nepáchnoucích aromatických thiolu
CN102249936B (zh) * 2010-05-19 2014-09-17 江苏豪森医药集团有限公司 O-去甲基文拉法辛盐酸盐的水合物及其制备方法
US8933123B2 (en) 2010-10-08 2015-01-13 Cadila Healthcare Limited Polymorphic forms of O-desmethyl-venlafaxine succinate
WO2012140577A1 (en) 2011-04-12 2012-10-18 Lupin Limited Modified release pharmaceutical compositions of desvenlafaxine
CN104529797A (zh) * 2014-12-05 2015-04-22 南昌市博泽康医药科技有限公司 盐酸文拉法辛手性晶型的制备
MX367362B (es) 2016-06-29 2019-08-16 Alparis Sa De Cv Nuevas formas solidas de desvenlafaxina.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56324B1 (en) 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
CA2139000A1 (en) 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
AU4542893A (en) 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6010023124, Ｂｒ． Ｊ． Ｃｌｉｎ． Ｐｈａｒｍａｃｏｌ．, 1996, ４１, １４９−１５６ *
JPN6010023125, Ｃｈｉｒａｌｉｔｙ, 1992, ４, ８４−９０ *
JPN6010023126, Ｊ． Ｍｅｄ． Ｃｈｅｍ．, 1990, ３０, ２８９９−２９０５ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546718A (ja) * 2006-04-17 2008-12-25 テバ ファーマシューティカル インダストリーズ リミティド 実質的に純粋なｏ−デスメチルベンラファキシン及びその調製方法。
JP2008044936A (ja) * 2006-07-26 2008-02-28 Teva Pharmaceutical Industries Ltd Ｏ−デスメチルベンラファキシンの合成方法
JP2008088159A (ja) * 2006-07-26 2008-04-17 Teva Pharmaceutical Industries Ltd Ｏ−デスメチルベンラファキシンの合成方法
JP2008545807A (ja) * 2006-07-26 2008-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｏ−デスメチルベンラファキシンの合成方法
JP4763788B2 (ja) * 2006-07-26 2011-08-31 テバ ファーマシューティカル インダストリーズ リミティド Ｏ−デスメチルベンラファキシンの合成方法

Also Published As

Publication number Publication date
WO2000032555A1 (en) 2000-06-08
US6197828B1 (en) 2001-03-06
WO2000032555A8 (en) 2001-05-25
CA2352321A1 (en) 2000-06-08
EP1135358A1 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
EP1466889B1 (en) O-Desmethylvenlafaxine succinate
US6441048B1 (en) Methods of treating affective disorders using derivatives of (-)-venlafaxine
US6197828B1 (en) Derivatives of (+)-venlafaxine and methods of preparing and using the same
HK1139380A (en) Derivatives of venlafaxine and methods of preparing and using the same
HK1115863A (en) Derivatives of venlafaxine and methods of preparing and using the same
HK1121133A (en) Derivatives of (-)-venlafaxine and methods of preparing and using the same
AU3106200A (en) Derivatives of (+)-venlafaxine and methods of preparing and using the same
AU2005200129A1 (en) Derivatives of (+)-venlafaxine and methods of preparing and using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100511

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101019